Carlsmed (CARL) vs Cerus (CERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Carlsmed (CARL) has outperformed Cerus (CERS) over the past year, gaining 39.5% versus a gain of 14.2%. Carlsmed is the larger company by market cap ($477.4 million vs $373.6 million), about 1.3 times the size. Cerus converts more of its revenue into profit, with a net margin of -6.7% versus -58.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CARL | CERS |
|---|---|---|
| Share price | $17.42 | $1.85 |
| Market cap | $477.38M | $373.62M |
| 1-day change | +1.16% | -2.63% |
| YTD return | +41.05% | -10.19% |
| 1-year return | +39.47% | +14.20% |
| 5-year return | — | -73.50% |
| Forward P/E | — | 123.33 |
| EPS (TTM) | $-1.13 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.51M | $233.80M |
| Revenue growth (YoY) | +85.94% | +16.13% |
| Net income (latest FY) | $-29.63M | $-15.63M |
| Gross margin | 75.31% | — |
| Operating margin | -60.53% | -3.71% |
| Net margin | -58.67% | -6.68% |
| 52-week high | $19.15 | $3.47 |
| 52-week low | $8.50 | $1.59 |
| Distance from 52-week high | -9.05% | -46.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.29% | +177.30% |
| Average volume | 112.80K | 2.12M |
| Shares outstanding | 27.40M | 201.95M |
| Employees | 127 | 261 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CARL has outperformed CERS by 25.3 percentage points over the past year.
- Cerus is more profitable, keeping -6.7 cents of every revenue dollar as net income versus -58.7 cents for Carlsmed.
- Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs +16.13%).
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Health Care · Medical/Dental Instruments · 261 employees
CARL vs CERS FAQ
Which is bigger, Carlsmed or Cerus?
Carlsmed (CARL) is larger, with a market capitalization of $477.38M compared with $373.62M for Cerus (CERS).
Which stock has performed better over the past year, CARL or CERS?
CARL returned +39.47% over the past 12 months, compared with +14.20% for CERS (price return, excluding dividends). Past performance does not predict future results.
Are Carlsmed and Cerus in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.